mhurhangee/ep-ind-claims huggingface dataset:
A method for treating wastewater by separating organic matter from the wastewater, comprising the steps of: a. introducing wastewater into a treatment facility, wherein the treatment facility comprises a grit chamber and aeration bath; b. removing a portion of the wastewater from the aeration bath; c. supersaturating said portion of the wastewater with oxygen to form a supersaturated liquid that has an oxygen concentration sufficient to elevate dissolved oxygen in the wastewater being treated in the facility to a sufficient level for effective separation of the organic matter from the wastewater; d. introducing the supersaturated liquid into the wastewater in the aeration bath; and e. discharging the treated wastewater from the facility, wherein the step of supersaturating the wastewater further includes the steps of filtering the wastewater for filtering suspended material down to 400-1500 microns, and introducing the filtered wastewater into a surface tension modification generator (STMG) for forming supersaturated oxygenated water, and wherein prior to the step of filtering the wastewater, the solids content of the wastewater has been lowered to a particle size of <6.4 mm (<1/4") size or less. a. introducing wastewater into a treatment facility, wherein the treatment facility comprises a grit chamber and aeration bath; b. removing a portion of the wastewater from the aeration bath; c. supersaturating said portion of the wastewater with oxygen to form a supersaturated liquid that has an oxygen concentration sufficient to elevate dissolved oxygen in the wastewater being treated in the facility to a sufficient level for effective separation of the organic matter from the wastewater; d. introducing the supersaturated liquid into the wastewater in the aeration bath; and e. discharging the treated wastewater from the facility, wherein the step of supersaturating the wastewater further includes the steps of filtering the wastewater for filtering suspended material down to 400-1500 microns, and introducing the filtered wastewater into a surface tension modification generator (STMG) for forming supersaturated oxygenated water, and wherein prior to the step of filtering the wastewater, the solids content of the wastewater has been lowered to a particle size of <6.4 mm (<1/4") size or less. wherein the step of supersaturating the wastewater further includes the steps of filtering the wastewater for filtering suspended material down to 400-1500 microns, and introducing the filtered wastewater into a surface tension modification generator (STMG) for forming supersaturated oxygenated water, and wherein prior to the step of filtering the wastewater, the solids content of the wastewater has been lowered to a particle size of <6.4 mm (<1/4") size or less.
A pharmaceutical composition for use in the treatment or prevention of cancer in an HLA-A*0201-positive subject, wherein said pharmaceutical composition comprises an eEF2 peptide consisting of an amino acid sequence composed of contiguous amino acids derived from an eEF2 protein, wherein the amino acid sequence is selected from: (a) Leu Ile Leu Asp Pro Ile Phe Lys Val (SEQ ID NO:14); and (b) the amino acid sequence Leu Ile Leu Asp Pro Ile Phe Lys Val (SEQ ID NO:14) having a substitution of the amino acid Ile at position 2 with Leu or Met, and/or a substitution of the amino acid Val at position 9 with Leu. (a) Leu Ile Leu Asp Pro Ile Phe Lys Val (SEQ ID NO:14); and (b) the amino acid sequence Leu Ile Leu Asp Pro Ile Phe Lys Val (SEQ ID NO:14) having a substitution of the amino acid Ile at position 2 with Leu or Met, and/or a substitution of the amino acid Val at position 9 with Leu.
Planar filtration element (10, 60), comprising a rigid planar support structure (11, 61) and at least one filtration layer (12, 13, 52, 62) made of a membrane material, wherein the planar support structure comprises first and second opposite outer surface layers (111, 112) spaced apart and secured to each other at a multitude of points distributed throughout the support structure by spacing members extending between the first and second outer surface layers, thus defining a drainage compartment between said first and second outer surface layers (111, 112), which is configured to drain filtrate, wherein at least one of said first and second outer surface layers comprises through-openings in fluid connection with the drainage compartment, wherein the through-openings are distributed throughout the outer surface layers and do not have internal connections between one another within the outer surface layer, wherein said at least one outer surface layer (111, 112), when one disregards the through-openings (115, 515, 615), is formed of a material extending continuously throughout the outer surface layer, wherein the at least one filtration layer (12, 13, 52, 62) covers the at least one outer surface layer (111, 112) including the through-openings (115, 515, 615), and wherein the at least one filtration layer is porous; characterised in that: the first and second outer surface layers are formed with sheets, foils or skins having a thickness between 200 μm and 750 μm, and the membrane material of the filtration layer (12, 13, 52, 62) penetrates the through-openings, thus forming protuberances (122, 521, 622) towards the drainage compartment, the protuberances having sizes larger than sizes of the through-openings (115, 515, 615), thus forming undercut-type anchors for anchoring the filtration layer to the support structure, wherein the at least one filtration layer comprises an outer skin facing away from the filtration element, an inner skin on the protuberances facing towards the drainage compartment and a core comprising interconnected inner pores, wherein the inner pores are larger than pores of the outer skin and the inner skin. the first and second outer surface layers are formed with sheets, foils or skins having a thickness between 200 μm and 750 μm, and the membrane material of the filtration layer (12, 13, 52, 62) penetrates the through-openings, thus forming protuberances (122, 521, 622) towards the drainage compartment, the protuberances having sizes larger than sizes of the through-openings (115, 515, 615), thus forming undercut-type anchors for anchoring the filtration layer to the support structure, wherein the at least one filtration layer comprises an outer skin facing away from the filtration element, an inner skin on the protuberances facing towards the drainage compartment and a core comprising interconnected inner pores, wherein the inner pores are larger than pores of the outer skin and the inner skin.
A method for producing marine ostracod crustacean luciferin represented by a general formula, characterized in that a compound represented by a general formula is reacted with a compound represented by a general formula: wherein R 1 and R 2 are the same or different, represent straight or branched alkoxy groups having 1 to 6 carbon atoms, or benzyloxy groups which may be substituted, or R 1 and R 2 are taken together to represent an alkylenedioxy group; R 3 represents an aryl group which may be substituted or a heterocyclic group which may be substituted; Y 1 represents an alkylene group having 1 to 6 carbon atoms or an alkenylene group having 1 to 6 carbon atoms which may be substituted; and Z 1 represents an amino group, amino group mono-substituted with the straight or branched alkyl group having 1 to 6 carbon atoms, amino group di-substituted with the straight or branched alkyl group having 1 to 6 carbon atoms, guanidino group, amidino group, or an amino group, guanidino group or amidino group protected with a protecting group.
A composition comprising angiotensin II for use in the treatment of hypotension in a human patient, the treatment comprising: determining whether the patient received an angiotensin converting enzyme inhibitor (ACE inhibitor) within a preceding period of time of 1 hour to 7 days; and if the patient received an ACE inhibitor within the preceding period of time administering to the patient the composition comprising angiotensin II at an initial rate of less than or equal to 5 ng/kg/min. determining whether the patient received an angiotensin converting enzyme inhibitor (ACE inhibitor) within a preceding period of time of 1 hour to 7 days; and if the patient received an ACE inhibitor within the preceding period of time administering to the patient the composition comprising angiotensin II at an initial rate of less than or equal to 5 ng/kg/min.
An interface for a centrifugal fan comprising: an inlet shroud of an impeller; an air intake positioned in overlapping arrangement with a portion of the inlet shroud; and a clearance defined between the inlet shroud and the air intake, wherein the clearance forms a labyrinth fluid flow path for a leakage air flow; wherein a flange extends from an exterior surface of the inlet shroud at a generally central portion thereof; and characterized in that the free end of the flange and an adjacent end of the inlet shroud are beveled at an angle towards the central axis X about which the inlet shroud rotates. an inlet shroud of an impeller; an air intake positioned in overlapping arrangement with a portion of the inlet shroud; and a clearance defined between the inlet shroud and the air intake, wherein the clearance forms a labyrinth fluid flow path for a leakage air flow; wherein a flange extends from an exterior surface of the inlet shroud at a generally central portion thereof; and characterized in that the free end of the flange and an adjacent end of the inlet shroud are beveled at an angle towards the central axis X about which the inlet shroud rotates.
A method comprising: performing by a wireless communication device in an Idle mode, mobility management measurements only in macro cells, wherein in the Idle mode, the wireless communication device is neither provided with a control plane nor with a user plane; sending, by a macro cell, a configuration message to the wireless communication device in the Idle mode, the configuration message comprising a configuration of measurement reporting; the configuration of measurement reporting being configured so that the wireless communication device can perform a measurement of one or more indirect network connection nodes, such as virtual cells or local cells, for providing a user plane as well as macro Cells. according to configured setup of measurement reporting; and providing, by the macro cell, a control plane to the wireless communication device; and performing, by the wireless communication device a measurement of one or more indirect network connection nodes for providing a user plane as well as macro cells, according to configured setup of measurement reporting, an indirect network connection node being a network connection node that is indirectly connected to the network. performing by a wireless communication device in an Idle mode, mobility management measurements only in macro cells, wherein in the Idle mode, the wireless communication device is neither provided with a control plane nor with a user plane; sending, by a macro cell, a configuration message to the wireless communication device in the Idle mode, the configuration message comprising a configuration of measurement reporting; the configuration of measurement reporting being configured so that the wireless communication device can perform a measurement of one or more indirect network connection nodes, such as virtual cells or local cells, for providing a user plane as well as macro Cells. according to configured setup of measurement reporting; and providing, by the macro cell, a control plane to the wireless communication device; and performing, by the wireless communication device a measurement of one or more indirect network connection nodes for providing a user plane as well as macro cells, according to configured setup of measurement reporting, an indirect network connection node being a network connection node that is indirectly connected to the network.
A chewable tablet comprising a population of particles and an active pharmaceutical ingredient, the population of particles comprising directly compressible and non-directly compressible (non-DC) sugar alcohol particles, excluding non-DC erythritol particles, the non-DC sugar alcohol particles having not been granulated prior to tableting and providing the tablet with a plurality of discrete non-DC areas, each being composed of a single non-DC sugar alcohol particle or comprising several non-DC sugar alcohol particles, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet.
A central body for a gas escape channel of a turbojet engine, comprising an external wall and at least one internal wall forming at least on cavity between them, the external wall comprising multiple orifices drilled on at least one upstream section, in a way to form at least one Helmholtz resonator with the cavity, characterised in that the internal wall includes a flexible sleeve.
An electrode (114, 200) for providing electrotherapy from an ambulatory electrotherapy device comprising: at least one reservoir comprising a conductive gel; at least one pressure source (240, 300, 400) comprising a chemical reaction chamber comprising a first chemical (306, 406) and a second chemical (308, 408) isolated from each other by a mechanical barrier (310, 410), wherein the mechanical barrier is configured to be compromised upon receiving a signal from an electrotherapy device controller, and wherein the first chemical (306, 406) and the second chemical (308, 408) come into contact when the mechanical barrier (310, 410) is compromised to produce a sufficient amount of pressurized fluid to generate a sufficient pressure within the chamber to effect deployment of the conductive gel from the reservoir. at least one reservoir comprising a conductive gel; at least one pressure source (240, 300, 400) comprising a chemical reaction chamber comprising a first chemical (306, 406) and a second chemical (308, 408) isolated from each other by a mechanical barrier (310, 410), wherein the mechanical barrier is configured to be compromised upon receiving a signal from an electrotherapy device controller, and wherein the first chemical (306, 406) and the second chemical (308, 408) come into contact when the mechanical barrier (310, 410) is compromised to produce a sufficient amount of pressurized fluid to generate a sufficient pressure within the chamber to effect deployment of the conductive gel from the reservoir.
A colon-targeted composition of a biological active component, comprising hydroxypropyl methylcellulose, biological active component and auxiliary material, wherein the weight percentage of the hydroxypropyl methylcellulose is 40-90%, the weight percentage of the biological active component is 10-40%, and the weight percentage of the auxiliary material is 0-50%; and wherein the viscosity of the hydroxypropyl methylcellulose is 15,000 mPa·s-200,000 mPa·s and the biological active component is microorganisms.
A battery suitable to deliver stored energy at above 130°C for a period of greater than five hours, comprising: a cathode comprising carbon monofluoride; an anode comprising lithium metal; a separator; and an electrolyte which comprises an organosilicon compound of the formula: wherein R 1 is selected from the group consisting of alkyl moieties of less than five carbons, and wherein R 5, R 6 and R 7 are the same or different, and each is selected from the group consisting of alkyl moieties of less than five carbons; wherein R 2, R 3 and R 4 are the same or different, and each is selected from the group consisting of alkyl moieties of less than five carbons and R 8 -O(CH 2 CH 2 O) r -, where R 8 is selected from the group consisting of alkyl moieties of less than five carbons; wherein m is equal to or higher than 0 and lower than 11; and wherein r and n are the same or different and equal to or higher than 1 and lower than 10. a cathode comprising carbon monofluoride; an anode comprising lithium metal; a separator; and an electrolyte which comprises an organosilicon compound of the formula: wherein R 1 is selected from the group consisting of alkyl moieties of less than five carbons, and wherein R 5, R 6 and R 7 are the same or different, and each is selected from the group consisting of alkyl moieties of less than five carbons; wherein R 2, R 3 and R 4 are the same or different, and each is selected from the group consisting of alkyl moieties of less than five carbons and R 8 -O(CH 2 CH 2 O) r -, where R 8 is selected from the group consisting of alkyl moieties of less than five carbons; wherein m is equal to or higher than 0 and lower than 11; and wherein r and n are the same or different and equal to or higher than 1 and lower than 10. wherein R 1 is selected from the group consisting of alkyl moieties of less than five carbons, and wherein R 5, R 6 and R 7 are the same or different, and each is selected from the group consisting of alkyl moieties of less than five carbons; wherein R 5, R 6 and R 7 are the same or different, and each is selected from the group consisting of alkyl moieties of less than five carbons; wherein R 2, R 3 and R 4 are the same or different, and each is selected from the group consisting of alkyl moieties of less than five carbons and R 8 -O(CH 2 CH 2 O) r -, where R 8 is selected from the group consisting of alkyl moieties of less than five carbons; wherein m is equal to or higher than 0 and lower than 11; and wherein r and n are the same or different and equal to or higher than 1 and lower than 10.
An X-ray spectrometer for carrying out both an element analysis and a structural analysis of a polycrystalline sample, comprising a) a polychromatic source for providing a beam of X-rays that are incident on the sample, b) a holding device for holding the sample, c) one or more fluorescence channels which can select X-ray beams of a particular wavelength and energy and which have detectors for measuring the selected X-ray beams; d) at least one diffractometry channel which is configured to select, by means of a monochromator, an X-ray beam wavelength of the source subsequent to diffraction of the X-ray beams by the sample and having a detector for measuring the selected X-ray beams, wherein a single slit device is provided between the source and the sample which can be moved transversely relative to a direction of the beam exiting the source, and the monochromator of the diffractometry channel is stationarily disposed with respect to the source and the sample and has an entry single slit which defines, together with the movable single slit device and the sample position, a characteristic diffraction angle 2Θ of a predetermined crystal structure of the polycrystalline sample at a wavelength of the source selected by the monochromator. a) a polychromatic source for providing a beam of X-rays that are incident on the sample, b) a holding device for holding the sample, c) one or more fluorescence channels which can select X-ray beams of a particular wavelength and energy and which have detectors for measuring the selected X-ray beams; d) at least one diffractometry channel which is configured to select, by means of a monochromator, an X-ray beam wavelength of the source subsequent to diffraction of the X-ray beams by the sample and having a detector for measuring the selected X-ray beams,
A microphone arrangement (100, 100', 100") comprising at least three groups of microphones (112, 114, 116) that are mounted on a head-wearable support structure, the at least three groups of microphones comprising a first group of microphones with one or more microphones, a second group of microphones with one or more microphones, and a third group of microphones with one or more microphones, wherein the first group is mounted to a first casing that accommodates a signal transmission circuitry, the first casing being formed as part of a first earpad, the second group is mounted on a slider (135, 510) that is arranged to slide the microphones of the second group with respect to the first casing between a closed position and an opened position, wherein the first group of microphones and the second group of microphones define a combined directional array of microphones when the slider is in the opened position providing a directional signal that is directed to a mouth of a user for receiving the user's voice when the microphone arrangement is head-worn, characterized in that the third group comprises: at least one microphone that is arranged on the support structure so as to exhibit less sensitivity for sound coming from a user's mouth than for sound coming from a user's environment when the microphone arrangement is head-worn, wherein noise within the directional signal is reduced by processing the directional signal with a noise filter that is adapted with respect to a noise signal received by the third group of microphones. the third group comprises: at least one microphone that is arranged on the support structure so as to exhibit less sensitivity for sound coming from a user's mouth than for sound coming from a user's environment when the microphone arrangement is head-worn, wherein noise within the directional signal is reduced by processing the directional signal with a noise filter that is adapted with respect to a noise signal received by the third group of microphones.